Group III mGlu receptor agonist, ACPT-I, attenuates morphine-withdrawal symptoms after peripheral administration in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 8, 2009, Pages 1454-1457

  Pałucha Poniewiera, Agnieszka ^a   Novák, Kinga ^a   Pilc, Andrzej ^a,b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

ACPT I; Group III mGlu receptors; Morphine; Opiate withdrawal

Indexed keywords

1 AMINOCYCLOPENTANE 1,3,4 TRICARBOXYLIC ACID; ACPT 1; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; MORPHINE; NALOXONE; OPIATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; LOCOMOTION; MALE; MORPHINE ADDICTION; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; TREATMENT OUTCOME; TREMOR; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ANALYSIS OF VARIANCE; ANIMALS; BODY WEIGHT; CYCLOPENTANES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEAD MOVEMENTS; MALE; MICE; MICE, INBRED C57BL; MORPHINE; MORPHINE DEPENDENCE; MOTOR ACTIVITY; NALOXONE; NARCOTIC ANTAGONISTS; RECEPTORS, METABOTROPIC GLUTAMATE; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TREMOR; TRICARBOXYLIC ACIDS;

EID: 71549126798     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.07.029     Document Type: Article

References (28)

1. Aghajanian G.K., Kogan J.H., and Moghaddam B. Opiate withdrawal increases glutamate and aspartate efflux in the locus coeruleus: an in vivo microdialysis study. Brain Res 636 (1994) 126-130
2. Baskys A., and Malenka R.C. Agonists at metabotropic glutamate receptors presynaptically inhibit EPSCs in neonatal rat hippocampus. J Physiol 444 (1991) 687-701
3. Bisaga A., Comer S.D., Ward A.S., Popik P., Kleber H.D., and Fishman M.W. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology 157 (2001) 1-10
4. Bonci A., and Williams J.T. Increased probability of GABA release during withdrawal from morphine. J Neurosci 17 (1997) 796-803
5. Desai M.A., McBain C.J., Kauer J.A., and Conn P.J. Metabotropic glutamate receptor-induced disinhibition is mediated by reduced transmission at excitatory synapses onto interneurons and inhibitory synapses onto pyramidal cells. Neurosci Lett 181 (1994) 78-82
6. Fundytus M.E., Ritchie J., and Coderre T.J. Attenuation of morphine withdrawal symptoms by subtype - selective metabotropic glutamate receptor antagonists. Br J Pharmacol 120 (1997) 1015-1020
7. Gereau R.W., and Conn P.J. Multiple presynaptic metabotropic glutamate receptors modulate excitatory and inhibitory synaptic transmission in hippocampal area CA1. J Neurosci 15 (1995) 6879-6889
8. Goudet C., Chapuy E., Alloui A., Acher F., Pin J.P., and Eschalier A. Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain. Pain 137 (2008) 112-124
9. Guo M., Xu N.J., Li Y.T., Yang J.Y., Wu C.F., and Pei G. Morphine modulates glutamate release in the hippocampal CA1 area in mice. Neurosci Lett 381 (2005) 12-15
10. Hack S.P., Vaughan C.W., and Christie M.J. Modulation of GABA release during morphine withdrawal in midbrain neurons in vitro. Neuropharmacology 45 (2003) 575-584
11. Hao Y., Yang J.Y., Guo M., Wu C.F., and Wu M.F. Morphine decreases extracellular levels of glutamate in the anterior cingulate cortex: an in vivo microdialysis study in freely moving rats. Brain Res 1040 (2005) 191-196
12. Kłodzińska A., Chojnacka-Wójcik E., Pałucha A., Brański P., Popik P., and Pilc A. Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 38 (1999) 1831-1839
13. Koerner J.F., and Cotman C.W. Micromolar L-2-amino-4-phosphonobutyric acid selectively inhibits perforant path synapses from lateral entorhinal cortex. Brain Res 216 (1981) 192-198
14. Kogo N., Dalezios Y., Capogna M., Ferraguti F., Shigemoto R., and Somogyi P. Depression of GABAergic input to identified hiocampal neurons by group III metabotropic glutamate receptors in the rat. Eur J Neurosci 19 (2004) 2727-2740
15. Laurie D.J., Schoeffter P., Wiederhold K.H., and Sommer B. Cloning, distribution and functional expression of the human mGlu6 metabotropic glutamate receptor. Neuropharmacology 36 (1997) 145-152
16. Noriega N.C., Garyfallou V.T., Kohama S.G., and Urbanski H.F. Glutamate receptor subunit expression in the rhesus macaque locus coeruleus. Brain Res 1173 (2007) 53-65
17. Pałucha A., Brański P., and Pilc A. Selective mGlu5 receptor antagonist MTEP attenuates naloxone-induced morphine with-drawal symptoms. Pol J Pharmacol 56 (2004) 863-866
18. Pałucha-Poniewiera A., Kłodzińska A., Stachowicz K., Tokarski K., Hess G., Schann S., et al. Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents. Neuropharmacology 55 (2008) 517-524
19. Parsons C.G., Danysz W., and Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 11 (1998) 523-569
20. Rasmussen K., Krystal J.H., and Aghajanian G.K. Excitatory amino acids and morphine withdrawal: differential effects of central and peripheral kynurenic acid administration. Psychopharmacology 105 (1991) 508-512
21. Rasmussen K., Fuller R.W., Stockton M.E., Perry K.W., Swinford R.M., and Ornstein P.L. NMDA receptor antagonists suppress behaviors but not norepinephrine turnover of locus coeruleus unit activity induced by opiate withdrawal. Eur J Pharmacol 117 (1991) 9-16
22. Rasmussen K., Kendrick W.T., Kogan J.H., and Aghajanian G.K. A selective AMPA antagonists LY293558, antagonizes morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropsychopharmacology 15 (1996) 497-505
23. Rasmussen K., Martin H., Berger J.E., and Seager M.A. The mGlu5 receptor antagonists MPEP and MTEP attenuate behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons in rats. Neuropharmacology 48 (2005) 173-180
24. Schoepp D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 299 (2001) 12-20
25. Semyanov A., and Kullmann D.M. Modulation of GABAergic signaling among interneurons by metabotropic glutamate receptors. Neuron 25 (2000) 663-672
26. Tokuyama S., Wakabayashi H., and Ho I.K. Direct evidence for a role of glutamate in the expression of the opioid withdrawal syndrome. Eur J Pharmacol 295 (1996) 123-129
27. Vandergriff J., and Rasmussen K. The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropharmacology 38 (1999) 217-222
28. Zhang T., Feng Y., Rockhold R.W., and Ho I.K. Naloxone-precipitated morphine withdrawal increases pontine glutamate levels in the rat. Life Sci 55 (1994) L25-L31